OFEV

November 16, 2015May 12, 2016

Boehringer Ingelheim’s IPF Therapy OFEV Shows Further Safety, Efficacy

Boehringer Ingelheim presented new analyses showing OFEV® continued to be safe and tolerable for the treatment of idiopathic pulmonary fibrosis (IPF) in clinical use and in an extension study. The analyses ... Read more

October 29, 2015November 5, 2015

Boehringer Reports Efficacy of OFEV in Idiopathic Pulmonary Fibrosis Studies

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals, Inc., recently presented post-hoc analyses from the Phase III INPULSIS™ clinical trials at the American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada. Results ... Read more

October 29, 2015November 5, 2015

Disease-Relevant In Vitro and In Vivo Models for Lung Fibrosis Focus of Webinar

Idiopathic Pulmonary Fibrosis, News

On Nov. 12, 2015, experts from Charles River will host a live broadcast presentation through Xtalks entitled “Disease Relevant In Vitro and In Vivo Models for Lung Fibrosis” in which they will provide a series of ... Read more

September 29, 2015September 30, 2015

New Clinical Trial Data Shows IPF Drug OFEV (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals

News

Ridgefield, Connecticut based Boehringer Ingelheim Pharmaceuticals, Inc. reports that an interim analysis of the open-label, single arm INPULSIS-ON extension trial of its drug OFEV (nintedanib) for treatment of the rare ... Read more

September 22, 2015November 6, 2015

Boehringer Ingelheim to Present New Data for COPD, IPF and Asthma at European Respiratory Society International Congress

Asthma, Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim plans to roll out several major presentations focusing for its respiratory disease portfolio at the upcoming European Respiratory Society (ERS) International Congress, September 26-30. The German company is currently ... Read more

July 16, 2015November 5, 2015

Boehringer Ingelheim Lauds 2015 IPF Treatment Guidelines for Recommending OFEV

Idiopathic Pulmonary Fibrosis, News

The recently published 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, which recommends using OFEV® (nintedanib) to treat patients diagnosed with idiopathic pulmonary fibrosis ... Read more

May 19, 2015November 5, 2015

Boehringer’s Idiopathic Pulmonary Fibrosis Therapy OFEV Shown To Be Safe, Effective in Longer-Term Study

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced new data on OFEV® (nintedanib) that further supports its efficacy, tolerability and safety in patients with idiopathic pulmonary fibrosis (IPF). The results were presented at the American ... Read more

January 19, 2015November 5, 2015

OFEV® (nintedanib*) Approved By The EU For Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim today announced that nintedanib has been approved by the European Commission (EC) for the treatment of idiopathic pulmonary fibrosis (IPF), joining the recent approval by the FDA in the U.S. back in October of ... Read more

November 5, 2014November 5, 2015

Omnicare Partners Up With Boehringer to Help IPF Patients Taking OFEV

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim has established a partnership with two divisions of Omnicare Specialty Care Group, which specializes in providing comprehensive pharmaceutical services designed to support their patients suffering from idiopathic pulmonary fibrosis ... Read more